China and US-based GluBio Therapeutics, which develops targeted protein degradation (TPD) drugs, has raised an extended Series A round of USD22m led by Qiming Venture Partners.
Lilly Asia Ventures and Kaitai Capital also took part. It brings total funding to nearly USD 90m since the company's inception in March 2021. Protein degraders tackle tough drug targets by taking over...
Black Sesame Technologies, a China-based chipmaker specializing in autonomous driving applications, has closed a Series C extension led by SummitView Capital. This brings the size of the overall round to USD 500m.
Japanese lower middle-market private equity firm J-Star has made an investment of undisclosed size in air cargo transportation and courier services provider Score Japan Holdings.
Gaorong Capital and Tsing Song Capital have led a CNY 500m (USD 74m) Series C for IntellectiveBio, a China-based contract development and manufacturing organisation (CDMO).
Morningside Venture Capital has teamed up with Kingray Capital, Trinity Innovation Fund, TigerYeah Capital, and FountainBridge Capital to provide USD 20m in angel and pre-Series A funding for Epigenic Therapeutics, a China-based gene editing specialist.